Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 
CORRESPONDENCE
Ahead of print publication  

Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma


1 Department of Internal Medicine, Texas Tech University of Health Sciences Center, El Paso, Texas, USA
2 Department of Pathology, Texas Tech University of Health Sciences Center, El Paso, Texas, USA
3 Division of Hematology/Oncology, Department of Internal Medicine, Texas Tech University of Health Sciences Center, El Paso, Texas, USA

Correspondence Address:
Nabeel Badri,
Department of Internal Medicine, Texas Tech University of Health Sciences Center, 4800 Alberta Avenue, El Paso, Texas 79905
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.JCRT_696_16

 > Abstract 


Diffuse large B-cell lymphomas (DLBCL) with MYC translocations combined with translocations involving BCL-2 or BCL-6 are referred to as double-hit lymphomas. These lymphomas are generally refractory to currently available therapies and have a poor prognosis. Primary mediastinal B-cell lymphoma (PMBL) is a rare subtype of DLBCL, which shares clinical, pathologic, and genetic similarities with classical Hodgkin's lymphoma. Unlike DLBCL, rearrangements involving MYC, BCL-2, and BCL-6 are typically absent in PMBL. We present a patient with PMBL who had increased gene copy numbers of MYC and BCL-2 along with increased protein expression of BCL-2 (c-Myc expression was about 15%–20% by immunostain). The disease was refractory to standard and salvage chemotherapies. The lymphoma, however, responded to brentuximab vedotin, a CD30-directed chemoimmunoconjugate.

Keywords: B-cell lymphomas 2, B-cell lymphomas 6, brentuximab, diffuse large B-cell lymphomas, MYC, primary mediastinal B-cell lymphoma



How to cite this URL:
Badri N, Ngamdu KS, Torabi A, Guar S. Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma. J Can Res Ther [Epub ahead of print] [cited 2019 Jan 16]. Available from: http://www.cancerjournal.net/preprintarticle.asp?id=244231

.






 

 
Top
 
 
  Search
 
     Search Pubmed for
 
    -  Badri N
    -  Ngamdu KS
    -  Torabi A
    -  Guar S
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  >Abstract
  In this article

 Article Access Statistics
    Viewed192    
    PDF Downloaded0    

Recommend this journal